干扰素抗肿瘤个性化标记物研究进展

潘驰; 黄建瑾

doi:10.3969/j.issn.1000-8179.2012.05.012

干扰素抗肿瘤个性化标记物研究进展

doi: 10.3969/j.issn.1000-8179.2012.05.012

潘驰,
黄建瑾^,

浙江大学医学院附属第二医院肿瘤内科, 浙江大学肿瘤研究所（杭州市310009）

详细信息

通讯作者:
黄建瑾 hhjj@medmail.com.cn

计量
- 文章访问数: 23
- HTML全文浏览量: 17
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2011-06-19
- 修回日期: 2011-09-29

Advances in Individualized Markers of Interferon in Anti-Cancer Therapy

Chi PAN,
Jianjin HUANG^,

Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University Medical School, Cancer Research Institute, Zhejiang University, Hangzhou 310009, China

More Information

Corresponding author: Jianjin HUANG, E-mail: hhjj@medmail.com.cn

摘要

摘要: 干扰素(interferon, IFN)是具有抗病毒、免疫调节和抗肿瘤等多种生物活性的细胞因子, 可应用于治疗多种肿瘤, 但在肿瘤治疗中的应用剂量往往较大, 因此给患者带来较严重的不良反应, 并且干扰素治疗仅能使部分患者获益。为了提高干扰素治疗的疗效, 并降低其不良反应, 近几年研究主要集中于探索其抗肿瘤机制和个性化标记物。最近研究发现, 许多干扰素相关的基因和蛋白的表达水平不仅与肿瘤发生有关, 还可预测干扰素治疗的敏感性和预后, 如干扰素调节因子(interferon regulatory factor, IRF)、IFNAR2 mRNA、microRNA、IFITM-1等, 其中检测外周血中的标记物极具有临床普及潜力。本文就近几年干扰素抗肿瘤个性化生物标记物的研究进展进行综述。
- 干扰素 /
- 个性化 /
- 生物指标 /
- 抗肿瘤 /
- 预测
Abstract: Interferon(IFN) is a cytokine with various biological functions, including antivirus, immuno-regulation and anti-tumor. It has been widely used in many anti-cancer therapies, including malignant melanoma, hepatocellular carcinoma, advanced renal -cell carcinoma, non-Hodgkin's lymphoma, chronic myelogenous leukemia and AIDS-related Kaposi's sarcoma.However, its effective dose is always very high, which may bring some serious side effects.Nevertheless, not all patients can benefit from the interferon therapy.In order to improve the curative effect of the interferon therapy, and lower its adverse side effects, the studies in recent years mainly focus on investigating the anti-tumor mechanism and the individualized markers of the interferon.So a problem we have faced is how to improve the efficiency and sensitivity of interferon? To solve this problem, many studies have been launched to find the effective prognostic factors and individualized biomarkers for guiding the treatment better.In addition, further clarifying the anti-tumor mechanisms of interferon is for the benefit of explaining how the biomarkers can predict prognosis of the patients.In recent studies, the expression of many interferon-related genes and proteins is not only related to the oncogenesis, but can predict the sensitivity of interferon therapy and its prognosis, such as interferon regulatory factor, IFNAR2 mRNA, microRNA and IFITM-1.Among them, some factors in the peripheral blood are of great potential in popularization of clinical practice, such as CD8highCD57+ lymphocyte levels in malignant melanoma, and serum IFNAR2 mRNA in mCRC.In this review, the advances of anti-tumorous individualized markers of interferon were briefly summarized.
- Interferon /
- Individualization /
- Biomarker /
- Anti-tumor /
- Prediction

HTML全文

参考文献(37)

[1]	Isaacs A, Lindenmann J. Virus interference. I. The interferon[J]. Proc R Soc Lond B Biol Sci, 1957, 147(927): 258-267. doi: 10.1098/rspb.1957.0048
[2]	Zhou Q, Zhang XS. Adjuvant interferon therapy for malignant melanoma: the debate[J]. Chin J Cancer, 2010, 29(11): 907-913. doi: 10.5732/cjc.010.10169
[3]	Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein[J]. J Leukoc Biol, 2002, 71(4): 565-581. http://www.jleukbio.org/cgi/reprint/71/4/565.pdf
[4]	Ito T, Amakawa R, Inaba M, et al. Differential regulation of human blood dendritic cell subsets by IFNs[J]. J Immunol, 2001, 166(5): 2961-2969. doi: 10.4049/jimmunol.166.5.2961
[5]	Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon - gamma[J]. Annu Rev Immunol, 1997, 15: 749-795. doi: 10.1146/annurev.immunol.15.1.749
[6]	Nishikawa H, Kato T, Tawara I, et al. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response[J]J Immunol, 2005, 175(7): 4433-4440.
[7]	Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions[J]. J Leukoc Biol, 2004, 75(2): 163-189. doi: 10.1189/jlb.0603252
[8]	Diaz A, Batista AE, Montero E. Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor[J]. J Interferon Cytokine Res, 2009, 29(8): 433-440. doi: 10.1089/jir.2008.0079
[9]	Fidler IJ. Regulation of neoplastic angiogenesis[J]. J Natl Cancer Inst Monogr, 2001, 2000(28): 10-14.
[10]	Ruiz-Ruiz C, Ruiz De Almodovar C, Rodriguez A, et al. The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1[J]. J Biol Chem, 2004, 279(19): 19712-19720. doi: 10.1074/jbc.M313023200
[11]	Levy-Strumpf N, Deiss LP, Berissi H, et al. DAP-5, a novel homolog of eukaryotic translation initiation factor 4G isolated as a putative modulator of gamma interferon-induced programmed cell death[J]. Mol Cell Biol, 1997, 17(3): 1615-1625. doi: 10.1128/MCB.17.3.1615
[12]	Subramaniam PS, Cruz PE, Hobeika AC, et al. Type I interferon induction of the Cdk-inhibitor p21WAFl is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line[J]. Oncogene, 1998, 16(14): 1885-1890. doi: 10.1038/sj.onc.1201712
[13]	Herzer K, Hofmann TG, Teufel A, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53[J]. Cancer Res, 2009, 69 (3): 855-862. doi: 10.1158/0008-5472.CAN-08-2831
[14]	Hosono T, Tanaka T, Tanji K, et al. NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation[J]. Br J Cancer, 2010, 102(5): 873-882. doi: 10.1038/sj.bjc.6605574
[15]	Wang J, Zhang W, Zhang Y, et al. c-Jun N-terminal kinase (JNK1) upregulates XIAP-associated factor 1(XAF1) through interferon regulatory factor 1(TRF- 1) in gastrointestinal cancer[J]. Carcinogenesis, 2009, 30(2): 222-229. http://www.onacademic.com/detail/journal_1000037969311410_48d9.html
[16]	Yamashita M, Toyota M, Suzuki H, et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae[J]. Cancer Sci, 2010, 101(7): 1708-1716. doi: 10.1111/j.1349-7006.2010.01581.x
[17]	Tokunaga T, Naruke Y, Shigematsu S, et al. Aberrant expression of interferon regulatory factor 3 in human lung cancer[J]. Biochem Biophys Res Commun, 2010, 397(2): 202-207. doi: 10.1016/j.bbrc.2010.05.085
[18]	Akagami M, Kawada K, Kubo H, et al". Transcriptional factor proxl plays an essential role in the antiproliferative action of interferon -gamma in esophageal cancer cells[J]. Ann Surg Oncol, 2011, 18(13): 3868-3877. doi: 10.1245/s10434-011-1683-6
[19]	Petrova TV Nykanen A, Norrmen C, et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype[J]. Cancer Cell, 2008, 13(5): 407-419. doi: 10.1016/j.ccr.2008.02.020
[20]	Wang L, Zhu J, Shan S, et al. Repression of interferon-gamma expression in T cells by Prospero-related homeobox protein[J]. Cell Res, 2008, 18(9): 911-920. doi: 10.1038/cr.2008.275
[21]	Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis[J]. J Nad Cancer Inst, 2010, 102(7): 493-501. doi: 10.1093/jnci/djq009
[22]	Monasters KM, Edwards MJ, Ross MI, et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma[J]. Ann Surg, 2010, 252(3): 460-466. doi: 10.1097/SLA.0b013e3181f20bb1
[23]	Meyer S, Wild PJ, Vogt T, et al. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma[J]. Exp Dermatol, 2010, 19(8): e251-e257. http://europepmc.org/abstract/MED/20500769
[24]	Gogas H, Kirkwood JM, Falk CS, et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon[J]. Cancer, 2010, 116(18): 4326-4333. doi: 10.1002/cncr.25211
[25]	Characiejus D, Pasukoniene V, Jonusauskaite R, et al. Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha[J]. Anticancer Res, 2008, 28(2B): 1139-1142. http://ar.iiarjournals.org/content/28/2B/1139.full.pdf
[26]	Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer[J]. N Engl J Med, 2009, 361(15): 1437-1447. doi: 10.1056/NEJMoa0901282
[27]	Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells[J]. Br J Cancer, 2010, 103 (10): 1617-1626. doi: 10.1038/sj.bjc.6605958
[28]	Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor[J]? Cancer Metastasis Rev, 2009, 28(3-4): 369-378.
[29]	Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression[J]. Br J Cancer, 2005, 93(5): 557-564. doi: 10.1038/sj.bjc.6602742
[30]	Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/beta- catenin signalling pathway induces chemoresistance to interferon -alpha/5-fluorouracil combination therapy for hepatocellular carcinoma[J]. BrJ Cancer, 2009, 100(10): 1647-1658. doi: 10.1038/sj.bjc.6605064
[31]	Vaglio A, Alberici F, Maggiore U, et al. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile[J]. Oncology, 2009, 76(1): 69-76. doi: 10.1159/000178810
[32]	Rini BI, Halabi S, Rosenberg JE, et al. PhaseⅢtrial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206[J]. J Clin Oncol, 2010, 28(13): 2137-2143. doi: 10.1200/JCO.2009.26.5561
[33]	Furuya N, Kamai T, Shirataki H, et al. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma[J]. Cancer Immunol Immunother, 2011, 60(6): 793-808. doi: 10.1007/s00262-011-0989-3
[34]	Shiba M, Nonomura N, Nakai Y, et al. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon -alpha administration in peripheral blood cells from renal cancer patients[J]. Int J Urol, 2009, 16(4): 356-359. doi: 10.1111/j.1442-2042.2009.02265.x
[35]	Zeimet AG, Reimer D, Wolf D, et al. Intrarumoral interferon regulatory factor(IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer[J]. Int J Cancer, 2009, 124(10): 2353-2360. doi: 10.1002/ijc.24214
[36]	Hatano H, Kudo Y, Ogawa I, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression[J]. Clin Cancer Res, 2008, 14(19): 6097-6105. doi: 10.1158/1078-0432.CCR-07-4761
[37]	刘宇虎, 柳娟, 郭健, 等. 干扰素诱导的跨膜蛋白-1对诊断结直肠癌的临床价值[J]. 南方医科大学学报, 2008, 28(11): 1950-1953. doi: 10.3321/j.issn:1673-4254.2008.11.023